Depression Screening Scores and Allergy and Gastrointestinal Medication Use in Adolescents

Between 2005 and 2014, the 12-month prevalence of major depressive episodes among adolescents aged 12 to 17 years increased from 8.5% to 11.3%. Adolescent-onset depression is related to increased risk for depression and suicidal attempts in adulthood. It is known that depression is an adverse effect...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug safety Vol. 18; no. 3; p. 335
Main Authors Harris, Kari, Saikumar, Pavithra, Sunkoj, Yojana, Vancuren, Trista, Olufowote, Blessing, Dedeaux, Julian
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2023
Subjects
Adolescent
Adult
Depression
Depressive Disorder, Major
Humans
Hypersensitivity
Over the counter
allergy
depression
teens
adolescents
gastrointestinal medication
Online AccessGet more information

Cover

More Information
Summary:Between 2005 and 2014, the 12-month prevalence of major depressive episodes among adolescents aged 12 to 17 years increased from 8.5% to 11.3%. Adolescent-onset depression is related to increased risk for depression and suicidal attempts in adulthood. It is known that depression is an adverse effect among adults taking OAM; however, the effect of OAM on adolescents is unknown. The aim of this study was to describe the relationship between Patient Health Questionnaire 9- Modified (PHQ9-M) scores and OAM use among adolescents. This study included data abstracted from charts of adolescents aged 12 to 21 years who completed a Kansas Be Healthy wellness appointment at the KUSM-W Peds Clinic in 2017. Odds ratios were used to calculate the relationship between oral allergy medication and gastrointestinal medication use among adolescents and PHQ9-M scores. Of the 425 adolescent charts analyzed, 22% (n=96) had positive PHQ9-M screens (a score of 10 or greater), and 13% (n=56) reported current use of allergy medication and/or GI medications. Adolescents taking oral allergy medication were 1.77 times more likely to have a positive PHQ9-M screen than those not taking oral allergy medication. Among adolescents on allergy medication, there was no difference in PHQ9- M scores based on the drug class (1st or 2nd generation antihistamine or Montelukast). Healthcare providers must diligently explore OAM/GI use with adolescents during clinical encounters and discuss possible adverse effects of OAM on mood.
ISSN:2212-3911
DOI:10.2174/1574886317666220826170140